SCHEMBL12465950

SCHEMBL12465950

N#CC1(CNc2nc(-c3ccnc(N[C@H]4CC[C@H](N)CC4)c3)ccc2F)CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 18/20 0.44
CDK9 P50750 11/20 0.42
CCNK O75909 4/20 0.42
CDK14 O94921 2/20 0.42
CDK1 P06493 2/20 0.42
CCNA2 P20248 2/20 0.42
CDK2 P24941 2/20 0.42
CDK5 Q00535 2/20 0.42
CDK16 Q00536 2/20 0.42
CCNB1 P14635 1/20 0.42
CDK7 P50613 1/20 0.42
CCNH P51946 1/20 0.42
MNAT1 P51948 1/20 0.42
CDK5R1 Q15078 1/20 0.42
CCNY Q8ND76 1/20 0.42
CDK17 Q00537 1/20 0.41
CDK18 Q07002 1/20 0.41
DYRK1B Q9Y463 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1192586 0.85 CCNT1 (0.58) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL1192583 0.85 CCNT1 (0.58) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL12465812 0.82 CDK9 (0.35) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL1192168 0.79 CCNT1 (0.58) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL1192167 0.79 CCNT1 (0.58) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL12465861 0.77 CDK9 (0.46) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL12465951 0.77 CCNT1 (0.62) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL12465949 0.77 CCNT1 (0.62) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL1192509 0.75 CCNT1 (0.61) CCNT1CDK9CCNKCDK14CDK1
SCHEMBL1192507 0.75 CCNT1 (0.61) CCNT1CDK9CCNKCDK14CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668162-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES Novartis AG (CH) 2013-12-04 EP disclosed
WO-2012101062-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed